Repligen Co. (NASDAQ:RGEN) Receives $176.82 Consensus Price Target from Brokerages

Shares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $176.82.

Several equities research analysts have issued reports on RGEN shares. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Canaccord Genuity Group dropped their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Finally, Royal Bank of Canada upped their price objective on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently made changes to their positions in the company. Signaturefd LLC boosted its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in Repligen during the fourth quarter worth about $29,000. Raiffeisen Bank International AG bought a new position in Repligen during the fourth quarter worth about $29,000. Itau Unibanco Holding S.A. bought a new stake in Repligen in the 4th quarter valued at about $40,000. Finally, Center for Financial Planning Inc. grew its position in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Trading Down 0.1 %

RGEN traded down $0.13 during midday trading on Tuesday, reaching $145.10. 233,800 shares of the company were exchanged, compared to its average volume of 707,975. The stock has a market capitalization of $8.15 billion, a P/E ratio of -284.38, a PEG ratio of 4.54 and a beta of 1.27. Repligen has a one year low of $102.97 and a one year high of $182.52. The stock's 50-day simple moving average is $139.81 and its 200 day simple moving average is $145.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.